Comparison of PD-L1 mRNA Expression Measured with the CheckPoint Typer® Assay with PD-L1 Protein Expression Assessed with Immunohistochemistry in Non-small Cell Lung Cancer

被引:26
|
作者
Erber, Ramona [1 ]
Stoehr, Robert [1 ]
Herlein, Stefanie [1 ]
Giedl, Claudia [1 ]
Rieker, Ralf Joachim [1 ]
Fuchs, Florian [2 ]
Ficker, Joachim H. [3 ]
Hartmann, Arndt [1 ]
Veltrup, Elke [4 ]
Wirtz, Ralph M. [4 ,5 ]
Brueckl, Wolfgang M. [3 ]
机构
[1] Friedrich Alexander Univ Erlangen Nurnberg FAU, Inst Pathol, Univ Hosp, Erlangen, Germany
[2] Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Med Gastroenterol Pneumonol & Endocrinol 1, Univ Hosp, Erlangen, Germany
[3] Paracelsus Med Univ Nuernberg, Gen Hosp Nuernberg, Dept Resp Med Allergol & Sleep Med, Nurnberg, Germany
[4] STRATIFYER Mol Pathol GmbH, Cologne, Germany
[5] St Elizabeth Hosp, Inst Pathol, Cologne, Germany
关键词
PD-L1; PD-1; NSCLC; lung cancer; pembrolizumab; nivolumab; E1L3N; 28-8; immunohistochemistry; EBUS-TBNA; mRNA; SQUAMOUS-CELL; NIVOLUMAB; DOCETAXEL;
D O I
10.21873/anticanres.12137
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Immunohistochemical (IHC) assessment of programmed death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC) has become important since the development of anti-PD-1/-PD-L1 directed drugs. Various PD-L1 antibodies and cut-offs have been used in different trials to predict response to these drugs, thus comparison of those studies is difficult. We compared PD-L1 mRNA expression measured by RT-qPCR with PD-L1 protein expression evaluated by IHC. Moreover, we investigated the impact of different tumour tissue acquisition methods on the reliability of PD-L1 measurement techniques. Materials and Methods: NSCLC cases (N=22), including n=9 mediastinal lymph node biopsies acquired by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and n=5 metastases, were evaluated prospectively for PD-L1 protein on tumor cells (TC) and immune cells (IC) using E1L3N and 28-8 antibodies and PD-L1 mRNA using the CheckPoint TYPER (R) assay. Results: In primary NSCLC tissues, agreement between PD-L1 mRNA and TC staining using the 28-8 antibody was excellent (kappa=0.85, p=0.0002). Comparing both PD-L1 antibodies against each other showed a kappa value of 0.58 (p=0.0106). In EBUS-TBNA, PD-L1 mRNA correlated perfectly with the 28-8 antibody (kappa=1.0, p=0.0023). PD-L1 mRNA levels significantly differed when comparing 28-8 TC staining of tumours >49% with 1-49% and 0% (p=0.0040; p=0.0081, respectively). In metastatic lesions, differences between PD-L1 mRNA and IHC became apparent (kappa=0.2, p=0.2525). Conclusion: Testing of PD-L1 mRNA and 28-8 IHC showed an excellent agreement in NSCLC samples including mediastinal lymph node biopsies. Since PD-L1 expression in >50% TC detected by 28-8 IHC can be reliably detected by RT-qPCR, quantitative PD-L1 mRNA determination should be considered as an alternative to IHC as there is no interobserver variability in RNA results.
引用
收藏
页码:6771 / 6778
页数:8
相关论文
共 50 条
  • [1] Comparison of PD-L1 mRNA expression measured with the CheckPointTyper® assay with PD-L1 protein expression assessed with immunohistochemistry (IHC) in lung cancer (NSCLC)
    Erber, R.
    Stoehr, R.
    Herlein, S.
    Fuchs, F.
    Veltrup, E.
    Wirtz, R.
    Hartmann, A.
    VIRCHOWS ARCHIV, 2017, 471 : S102 - S102
  • [2] Spatial heterogeneity of PD-L1 expression and the risk for misclassification of PD-L1 immunohistochemistry in non-small cell lung cancer
    Dori, Shani Ben
    Aizic, Asaf
    Sabo, Edmond
    Hershkovitz, Dov
    LUNG CANCER, 2020, 147 : 91 - 98
  • [3] Quantification of PD-L1 expression in non-small cell lung cancer
    Verma, Vivek
    Chang, Joe Y.
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S402 - S404
  • [4] PD-L1 expression testing in non-small cell lung cancer
    Teixido, Cristina
    Vilarino, Noelia
    Reyes, Roxana
    Reguart, Noemi
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [5] PD-L1 Expression in Patients with Non-small Cell Lung Cancer
    Masago, Katsuhiro
    Fujita, Shiro
    Hata, Akito
    Okuda, Chiyuki
    Kaji, Reiko
    Katakami, Nobuyuki
    Hirata, Yukio
    ANTICANCER RESEARCH, 2017, 37 (05) : 2269 - 2274
  • [6] Tumor Infiltrating Lymphocytes Are Associated with Epithelial Expression of PD-L1 Protein, PD-L1 mRNA and Better Outcome in Non-Small Cell Lung Cancer
    Schalper, K. A.
    Velcheti, V.
    Carvajal-Hausdorf, D. E.
    Anagnostou, V.
    Syrigos, K.
    Gettinger, S.
    Chen, L.
    Herbst, R.
    Rimm, D. L.
    MODERN PATHOLOGY, 2014, 27 : 493A - 494A
  • [7] Tumor Infiltrating Lymphocytes Are Associated with Epithelial Expression of PD-L1 Protein, PD-L1 mRNA and Better Outcome in Non-Small Cell Lung Cancer
    Schalper, K. A.
    Velcheti, V.
    Carvajal-Hausdorf, D. E.
    Anagnostou, V.
    Syrigos, K.
    Gettinger, S.
    Chen, L.
    Herbst, R.
    Rimm, D. L.
    LABORATORY INVESTIGATION, 2014, 94 : 493A - 494A
  • [8] Current PD-L1 immunohistochemistry for non-small cell lung cancer
    Scheel, Andreas H.
    Schaefer, Stephan C.
    JOURNAL OF THORACIC DISEASE, 2018, 10 (03) : 1217 - 1219
  • [9] PD-L1 immunohistochemistry in patients with non-small cell lung cancer
    Jotatsu, Takanobu
    Oda, Keishi
    Yatera, Kazuhiro
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S2127 - S2129
  • [10] Evaluation of PD-L1 mRNA and protein expression in non-small cell lung and hepatocellular carcinoma
    Jaeger, Savina
    Lee, Benjamin H.
    Mosher, Rebecca
    Shebnova, Olga
    Wang, Yan
    Yu, Yenyen
    Yang, David
    Murakami, Masato
    Greshock, Joel
    Schlegel, Robert
    Boral, Anthony
    Cao, Zhu Alexander
    CANCER RESEARCH, 2015, 75